Isopropyl-methyl-o-tolyl-amine | 2100-49-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Isopropyl-methyl-o-tolyl-amine
• 英文别名: N,2-dimethyl-N-propan-2-ylaniline
• CAS: 2100-49-4
• 化学式: C₁₁H₁₇N
• 分子量: 163.263
• InChiKey: GPSWDLOMNAYPBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  丙酮 、 N-甲基-邻甲基苯胺 在 三乙胺-硼烷 作用下， 以 neat (no solvent) 为溶剂， 100.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 以56%的产率得到Isopropyl-methyl-o-tolyl-amine
  参考文献：
  名称：

  使用 BH3N(C2H5)3 作为还原剂对酮/醛与胺进行还原胺化

  摘要：

  在此，我们报告了使用 BH 3 N(C 2 H 5 ) 3作为催化剂和还原剂在温和条件下用胺有效还原胺化酮/醛的第一个例子，以优异的产率提供各种叔胺和仲胺。机理研究表明，BH 3 N(C 2 H 5 ) 3具有促进亚胺和亚胺形成以及在还原胺化中作为还原剂的双重作用。

  DOI：

  10.1039/d1cc02618f

文献信息

• [EN] METHOD FOR PRODUCING 1-HEXENE<br/>[FR] PROCÉDÉ DE PRODUCTION D'1-HEXÈNE
  申请人：SUMITOMO CHEMICAL CO

  公开号：WO2012133937A1

  公开（公告）日：2012-10-04

  Disclosed is a method for producing 1-hexene that is capable of reducing the amount of by-product polymers when 1-hexene is produced through the trimerization reaction of ethylene. The method for producing 1-hexene comprises the following steps 1 and 2: step 1: the step of preparing a catalytic component by bringing a transition metal complex represented by any one of formulae (1-1) to (1-3) into contact with a specific organic aluminum compound in the absence of ethylene; and step 2: the step of trimerizing ethylene in the presence of a catalyst obtainable by bringing the catalytic component obtained in step 1 into contact with a specific boron compound.

  公开了一种生产1-己烯的方法，该方法能够在通过乙烯的三聚反应生产1-己烯时减少副产物聚合物的数量。生产1-己烯的方法包括以下步骤1和2：步骤1：通过将由式（1-1）到（1-3）中的任一表示的过渡金属配合物与特定有机铝化合物接触而制备催化组分，在没有乙烯的情况下；步骤2：在将在步骤1中获得的催化组分与特定硼化合物接触而获得的催化剂存在下，三聚乙烯。
• Viral Polymerase Inhibitors
  申请人：Beaulieu Louis Pierre

  公开号：US20070142380A1

  公开（公告）日：2007-06-21

  An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R 2 , R 3 , L, M 1 , M 2 , M 3 , M 4 , Y 1 , Y 0 , Z and Sp are as defined in claim 1 , or a salt thereof, as an inhibitor of HCV NS5B polymerase.

  一种化合物的同分异构体、对映异构体、非对映异构体或互变异构体，其化学式为I：其中A、B、R2、R3、L、M1、M2、M3、M4、Y1、Y0、Z和Sp如权利要求1所定义，或其盐，作为HCV NS5B聚合酶的抑制剂。
• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：Universal Display Corporation

  公开号：EP3750897A1

  公开（公告）日：2020-12-16

  Provided are organometallic compounds. Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

  提供的是有机金属化合物。还提供了包含这些有机金属化合物的配方。此外，还提供了使用这些有机金属化合物的有机发光二极管和相关消费产品。
• AZD9291 intermediate and preparation method therefor
  申请人：SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD.

  公开号：US10167275B2

  公开（公告）日：2019-01-01

  Disclosed are an intermediate, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-formamidine]phenyl-2-propenamide (II), applicable in preparing AZD9291 (I) and a preparation method for the intermediate. Preparation steps of the preparation method comprise: 2-fluoro-4-methoxyaniline, serving as a starting material, undergoes amidation, substitution, nitrification, reduction and guanidination reactions to prepare N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-formamidine]phenyl-2-propenamide (II). Also disclosed is a method for preparing AZD9291 (I) by means of a cyclization reaction between the compound of a formula II and (2E)-3-dimethylamino-1-(1-methyl-1H-indol-3-yl)-2-propen-1-one (III). The preparation method has readily available raw materials and a simple process and is economical, environmentally friendly, and suitable for industrialized production.

  本发明公开了一种适用于制备AZD9291（I）的中间体N-[2-[[2-（二甲基氨基）乙基]甲基氨基]-4-甲氧基-5-甲脒]苯基-2-丙烯酰胺（II）以及该中间体的制备方法。该制备方法的制备步骤包括：以 2-氟-4-甲氧基苯胺为起始原料，经过酰胺化、取代、硝化、还原和胍化反应制备 N-[2-[[2-（二甲基氨基）乙基]甲基氨基]-4-甲氧基-5-甲脒]苯基-2-丙烯酰胺（II）。还公开了一种通过式 II 化合物与 (2E)-3 二甲基氨基-1-(1-甲基-1H-吲哚-3-基)-2-丙烯-1-酮 (III) 的环化反应制备 AZD9291 (I) 的方法。该制备方法原料易得，工艺简单，经济环保，适合工业化生产。
• Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof
  申请人：INVENTISBIO SHANGHAI LTD.

  公开号：US10179784B2

  公开（公告）日：2019-01-15

  The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. See e.g., Formula I below. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

  本发明公开了一类嘧啶或吡啶化合物、其药学上可接受的盐、立体异构体、原药和溶液剂、其制备方法和药物组合物及其药物用途。参见下文式 I。这些化合物可以抑制表皮生长因子受体蛋白酶的变体，因此可以有效抑制多种肿瘤细胞的生长。这些化合物可用于制备抗肿瘤药物，用于治疗、联合治疗或预防各种不同的癌症。这些化合物可以克服现有的第一代表皮生长因子受体抑制剂（如吉非替尼、厄洛替尼等）引起的耐药性。特别是，这些化合物可用于制备治疗或预防由表皮生长因子受体变体（如 L858R 激活突变体、Exon19 缺失激活突变体和 T790M 耐药突变体）介导的疾病、紊乱、失调或病症的药物。